Neo-antigen specific T cell responses indicate the presence of metastases before imaging

V. S. Fear; C. A. Forbes; J. Chee; S. MA; S. Neeve; L. Celliers; S. A. Fisher; I. Dick; J. Creaney; B. W. S. Robinson

doi:10.1038/s41598-019-51317-3

journal article Open Access Oct 10, 2019

Neo-antigen specific T cell responses indicate the presence of metastases before imaging

V. S. Fear

C. A. Forbes J. Chee

S. MA

S. Neeve L. Celliers S. A. Fisher

I. Dick

J. Creaney B. W. S. Robinson

Scientific Reports Vol. 9 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/s41598-019-51317-3

Abstract

AbstractNon-small cell lung cancer (NSCLC) causes 19% of all Australian cancer deaths, with a 5-year survival post-resection of around 60%. Post-operative recurrence is due to metastases that were undetectable pre-operatively, or growth of microscopic locoregional residual disease. However, post-operative imaging modalities typically only detect more advanced tumours; where PET-CT has a detection limit of 6–7 mm. Detection of small deposits of lung metastatic disease is of importance in order to facilitate early and potentially more effective treatment. In this study, in a murine model of lung metastatic disease, we explore whether neo-antigen specific T cells are a sensitive marker for the detection of lung cancer after primary tumour resection. We determine lung metastatic disease by histology, and then compare detection by PET-CT and neo-antigen specific T cell frequency. Detection of lung metastatic disease within the histology positive group by PET-CT and neo-antigen specific T cell frequency were 22.9% and 92.2%, respectively. Notably, neo-antigen specific T cells in the lung draining lymph node were indicative of metastatic disease (82.8 ± 12.9 spots/105 cells; mean ± SE), compared to healthy lung control (28.5 ± 8.6 spots/105 cells; mean ± SE). Potentially, monitoring tumour neo-antigen specific T cell profiles is a highly sensitive method for determining disease recurrence.

Topics

No keywords indexed for this article. Browse by subject →

References

34

[1]

Sullivan, R. et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 16, 1193–2224 (2015). 10.1016/s1470-2045(15)00223-5

[2]

Yano, T., Okamoto, T., Fukuyama, S. & Maehara, Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J. Clin. Oncol. 5, 1048–1054 (2014). 10.5306/wjco.v5.i5.1048

[3]

Hiller, J., Brodner, G. & Gottschalk, A. Understanding clinical strategies that may impact tumour growth and metastatic spread at the time of cancer surgery. Best Pract. Res. Clin. Anaesthesiol. 27, 427–439 (2013). 10.1016/j.bpa.2013.10.003

[4]

Snyder, G. L. & Greenberg, S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br. J. Anaesth. 105, 106–115 (2010). 10.1093/bja/aeq164

[5]

Fisher, S. A. et al. Transient Treg depletion enhances therapeutic ant-cancer vaccination. Immunity, Inflammation and Disease. 5, 16–28 (2017). 10.1002/iid3.136

[6]

Calabro, L. et al. Tremilimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 14, 1104–1111 (2013). 10.1016/s1470-2045(13)70381-4

[7]

Nelson, D., Bundell, C. & Robinson, B. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes. J. Immunol. 165, 6123–6132 (2000). 10.4049/jimmunol.165.11.6123

[8]

Australian Institute of Health and Welfare. Cancer in Australia 2017. Cancer series no 101.Cat. no. CAN100. Canberra:AIHW. (2017).

[9]

Naidoo, R., Windsor, M. N. & Goldstraw, P. Surgery in 2013 and beyond. J. Thorac. Dis. 5(Suppl 5), S593–606 (2013).

[10]

Khanna, P., Blais, N., Gaudreau, P. O. & Corrales-Rodriguez, L. Immunotherapy Comes of Age in Lung Cancer. Clin. Lung Cancer. 18, 13–22 (2017). 10.1016/j.cllc.2016.06.006

[11]

Anyaegbu, C. C., Lake, R. A., Heel, K., Robinson, B. W. & Fisher, S. A. Chemotherapy enhances cross-presentation of nuclear tumor antigens. PLoS One. 9(9), e107894 (2014). 10.1371/journal.pone.0107894

[12]

Nelson, D. J. et al. Tumor progression despite efficient tumor antigen cross-presentation and effective “arming” of tumor antigen-specific CTL. J. Immunol. 166, 5557–5566 (2001). 10.4049/jimmunol.166.9.5557

[13]

Marzo, A. L., Lake, R. A., Robinson, B. W. & Scott, B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59, 1071–1079 (1999).

[14]

Creaney, J. et al. Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. Oncoimmunology. 4(7), e1011492 (2015). 10.1080/2162402x.2015.1011492

[15]

Wick, D. A. et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 20, 1125–34 (2014). 10.1158/1078-0432.ccr-13-2147

[16]

Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science. 348, 69–74 (2015). 10.1126/science.aaa4971

[17]

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg

Cell 2011 10.1016/j.cell.2011.02.013

[18]

Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 515, 577–81 (2014). 10.1038/nature13988

[19]

American Cancer Society. Non-Small Cell Lung Cancer, https://www.cancer.org/cancer/non-small-cell-lung-cancer.html (2016).

[20]

Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552–3559 (2008). 10.1200/jco.2007.13.9030

[21]

Hochhegger, B. et al. PET/CT imaging in lung cancer: indictations and findings. J. Bras. Pneumol. 41, 264–274 (2015). 10.1590/s1806-37132015000004479

[22]

Bamba, Y., Itabashi, M. & Kameoka, S. Value of PET/CT imaging for diagnosing pulmonary metastasis of colorectal cancer. Hepatogastroenterology. 58, 1972–1974 (2011). 10.5754/hge11256

[23]

Duan, F. et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 211, 2231–48 (2014). 10.1084/jem.20141308

[24]

Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015). 10.1038/nature14426

[25]

Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81–85 (2015). 10.1038/nm.3773

[26]

Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat, Med. 22, 433–438 (2016). 10.1038/nm.4051

[27]

Ye, L., Ma, S., Robinson, B. W. & Creaney, J. Immunotherapy strategies for mesothelioma – the role of tumour specific neoantigens in a new era of precision medicine. Expert Rev. Respir. Med. 13, 181–192 (2019). 10.1080/17476348.2019.1563488

[28]

Brown, M. D. et al. Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity. Oncoimmunology. 1, 1084–1094 (2012). 10.4161/onci.20924

[29]

Verdegaal, E. M. et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 536, 91–97 (2016). 10.1038/nature18945

[30]

Schoenberger, S. P. Neoantignes what are the major challenges, and how can these be overcome? Targeting the right antigens in the right patients. Cold Spring Harbour, Perspectives in Biology, https://doi.org/10.1101/cshperspect.a028837 (2017). 10.1101/cshperspect.a028837

[31]

Kalaora, S. et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 8, 1366–1375 (2018). 10.1158/2159-8290.cd-17-1418

[32]

Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J. & Robinson, B. W. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer. 52, 881–886 (1992). 10.1002/ijc.2910520609

[33]

Fear, V. S. et al. Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncoimmunology, 2018, 10.1080/2162402X.2018.1494111 (2018). 10.1080/2162402x.2018.1494111

[34]

Fear, V. S. et al. A pathogenic role for the integrin CD103 in experimental allergic airways disease. Physiol Rep 2016; 4(21), e13021, 10.148114/phy2.13021 (2016). 10.14814/phy2.13021

Metrics

4

Citations

34

References

Details

Published: Oct 10, 2019
Vol/Issue: 9(1)
License: View

Authors

Cite This Article

V. S. Fear, C. A. Forbes, J. Chee, et al. (2019). Neo-antigen specific T cell responses indicate the presence of metastases before imaging. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-51317-3

Neo-antigen specific T cell responses indicate the presence of metastases before imaging

You May Also Like